65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05505916
(ClinicalTrials.gov)
October 24, 202211/8/2022An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or IIHereditary AngioedemaDrug: KVD900 600 mgKalVista Pharmaceuticals, Ltd.NULLRecruiting12 YearsN/AAll150Phase 3United States;Australia;Bulgaria;France;Greece;Hungary;Netherlands;Spain;United Kingdom
2NCT05511922
(ClinicalTrials.gov)
October 24, 202211/8/2022PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialA Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 TrialHereditary AngioedemaDrug: KVD900 600 mgKalVista Pharmaceuticals, Ltd.NULLRecruiting12 Years17 YearsAll12Phase 3United States;Australia;Bulgaria;France;Greece;Spain;United Kingdom
3NCT05259917
(ClinicalTrials.gov)
February 23, 20224/2/2022A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or IIHereditary AngioedemaDrug: Placebo;Drug: KVD900 600 mg;Drug: KVD900 300 mgKalVista Pharmaceuticals, Ltd.NULLRecruiting12 YearsN/AAll114Phase 3United States;Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Puerto Rico;Romania;Spain;United Kingdom